New ALL drug

Besponsa is a targeted therapy from Pfizer for acute lymphoblastic leukemia or ALL treatment. It was included in the priority review list in China in March and is expected to be approved for the China market soon. There was no new drug for ALL patients in the country over the past decade.

As the world's first antibody drug conjugate targeting CD22 for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor ALL, it has been approved by the US Food and Drug Administration.

ALL accounts for 15 percent of all leukemia patients. Nearly half of ALL patients relapse with a median survival of only four to eight months.

Spiciest instant noodles

Samyang Food from South Korea, which will make its debut at the third CIIE, will exhibit its instant noodle product series famous for being spicy.

The instant noodle products with extremely spicy and a little sweet flavor have been chased after by some Chinese consumers since their debut in the market in recent years. In early 2019, a trading company in Ningbo city, Zhejiang province, signed an agreement with the South Korean company to work as the general sales agent for the latter to satisfy Chinese consumers' need for the products.